Correlations between plasma homocysteine and folate concentrations and carotid atherosclerosis in high-risk individuals: baseline data from the Homocysteine and Atherosclerosis Reduction Trial (HART)

Abstract

Homocysteine has been proposed as a risk factor for atherosclerosis. The association between plasma total homocysteine (tHcy) concentration and carotid atherosclerosis has not been thoroughly studied in high-risk populations with vascular disease. For this study, carotid atherosclerosis was assessed by measurements of carotid intima-media thickness (IMT) and plaque calcification in 923 patients with vascular disease or diabetes. Associations with tHcy and plasma folate concentrations were examined. The mean and single maximum carotid IMT were 1.27 ± 0.34 mm and 2.41 ± 0.83 mm, respectively. The mean segment plaque calcification score was 27.8%. tHcy correlated with mean (r = 0.13; p < 0.001) and single maximum (r = 0.12; p < 0.001) carotid IMT. There was a progressive increase in mean and single maximum carotid IMT across quartiles of tHcy (p < 0.0001 for trend). These associations were no longer significant after adjusting for other CV risk factors. A trend towards an inverse association between plasma folate and mean max carotid IMT was found in both univariate and multivariable analyses. However, the plaque calcification score increased across quartiles of tHcy (p < 0.01) and decreased across quartiles of plasma folate concentrations (p < 0.05) after multiple adjustments. In conclusion, in high-risk individuals, tHcy and low folate concentrations were only weakly associated with carotid IMT. In contrast, we found an independent association with the plaque calcification score, a measure of more advanced atherosclerosis. The effect of tHcy lowering on carotid atherosclerosis and stroke prevention warrants further investigation.

Keywords

carotid intima-media thickness folate homocysteine plaque

References

1 McCully KS . Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969; 56: 111–128.

2 Eikelboom JW Lonn E Genest J Hankey G Yusuf S . Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 1999; 131: 363–375.

3 Wald DS Law M Morris JK . Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002; 325: 1202–1206.

4 Klerk M Verhoef P Clarke R Bloom HJ Schouten EG . MTHFR 677C→T polymorphism and risk of coronary heart disease. JAMA 2002; 228: 2023–2031.

5 Boushey CJ Beresford AA Omenn GS Motulsky AG . A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049–1057.

6 Homocysteine Studies Collaboration . Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002; 288: 2015–2022.

7 Casas JP Bautista LE Smeeth L Sharma P Hingorani AD . Homocysteine and stroke: evidence on a causal link from mendelian randomization. Lancet 2005; 365: 224–232.

8 Harker LA Harlan JM Harker LA . Effect of sulfinpyrazone on homocysteine-induced endothelial injury and arteriosclerosis in baboons. Circ Res 1983; 53: 731–739.

9 Welch GN Loscalzo J . Homocysteine and atherothrombosis. N Engl J Med 1998; 338: 1042–1050.

10.

10 Harker LA Slichter SJ Scott CR Ross R . Homocysteinemia: vascular injury and arterial thrombosis. N Engl J Med 1974; 291: 537–543.

11.

11 Toole JF Malinow MR Chambless LE . Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death. The Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004; 291: 565–575.

12.

12 Lonn E Yusuf S Arnold MJ . Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in high-risk chronic vascular disease. N Engl J Med 2006; 354: 1567–1577.

13.

13 Bønaa KH Njølstad I Ueland PM . for the NORVIT Trial Investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006; 354: 1578–1588.

14.

14 Albert CM Cook NR Gaziano JM . A randomized trial of folic acid and B-vitamins in the secondary prevention of cardiovascular events in women: results from the Women’s Antioxidant and Folic Acid Cardiovascular Study (WAFACS); presented at the AHA, Chicago, USA; November, 2006.

15.

15 Loscalzo J . Homocysteine trials – clear outcomes for complex reasons. N Engl J Med 2006; 354: 1629–1632.

16.

16 Durga J Verhoef P Bots ML Schouten E . Homocysteine and carotid intima-media thickness: a critical appraisal of the evidence. Atherosclerosis 2004; 176: 1–19.

17.

17 Durga J Bots ML Schouten EG Kok FJ Verhoef P . Low concentrations of folate, not hyperhomocysteinemia, are associated with carotid intima-media thickness. Atherosclerosis 2005; 179: 285–292.

18.

18 Lonn E Held C Arnold JMO . The HOPE-2 Investigators. Rationale, design and baseline characteristics of a large, simple, randomized trial of combined folic acid and vitamins B6 and B12 in high-risk patients: The Heart Outcomes Prevention Evaluation (HOPE)-2 trial. Can J Cardiol 2006; 22: 47–53.

19.

19 Lonn E Yusuf S Dzavik V . for the SECURE Investigators. Effects of ramipril and vitamin E on atherosclerosis. The study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin (SECURE). Circulation 2001; 103: 919–925.

20.

20 Tsai MY Arnett DK Eckfeldt JH Wiliams RR Ellison RC . Plasma homocysteine and its association with carotid intimal-medial wall thickness and prevalent coronary heart disease: NHLBI Family Heart Study. Atherosclerosis 2000; 151: 519–524.

21.

21 McQuillan BM Beilby JP Nidorf M Thompson PL Hung J . Hyperhomocysteinemia but not the C677T mutation of methylenetetrahydrofolate reductase is an independent risk determinant of carotid wall thickening. The Perth Carotid Ultrasound Disease Assessment Study (CUDAS). Circulation 1999; 99: 2383–2388.

22.

22 Wald DS Morris JK Law M Wald NJ . Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence. BMJ 2006; 333: 1114–1117.

23.

23 Nandalur KR Baskurt E Hagspiel KD . Carotid artery calcification on CT may independently predict stroke risk. Am J Roentgenol 2006; 186: 547–552.

24.

24 Grogan JK Shaalan WE Gewertz B . B-mode ultrasonographic characterization of carotid atherosclerotic plaques in symptomatic and asymptomatic patients. J Vasc Surg 2005; 42: 435–441.

25.

25 Ray JG Vermeulen MG Boss SC Cole DE . Declining rate of folate insufficiency among adults following increased folic acid food fortification in Canada. Can J Public Health 2002; 93: 249–253.

26.

26 Robertson J Iemolo F Stabler SP Allen RH Spence D . Vitamin B12, homocysteine and carotid plaque in the era of folic acid fortification of enriched cereal grain products. CMAJ 2005; 172: 1569–1573.

27.

27 Till U Rohl P Jentsch A . Decrease of carotid intima-media thickness in patients at risk to cerebral ischemia after supplementation with folic acid, vitamins B6 and B12. Atherosclerosis 2005; 181: 131–135.

28.

28 Marcucci R Zanazzi M Bertoni E . Homocysteine-lowering therapy and carotid intima-media thickness in renal transplant recipients. Transplant Proc 2005; 37: 2491–2492.

29.

29 Bazzano LA Reynolds K Holder KN . Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. JAMA 2006; 296: 2720–2726.

30.

30 Spence JD Bang H Chambless LE Stampfer MJ . Vitamin intervention for stroke prevention trial. An efficacy analysis. Stroke 2005; 36: 2404–2409.

31.

31 Spence JD . Homocysteine. Call off the funeral. Stroke 2006; 37: 282–283.

32.

32 Wang X Qin X Demirtas H . Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 2007; 369: 1876–1882.